摘要
目的探讨PPAR-γ激动剂罗格列酮对糖尿病大鼠肾脏VEGF表达的影响。方法采用长期高脂饮食加小剂量链脲菌素(STZ)一次性腹腔注射,建立2型糖尿病大鼠模型,光镜及电镜行肾脏形态学检查;RT-PCR测定VEGFmRNA表达,VEGF免疫组化染色观察VEGF蛋白水平变化。结果2型糖尿病大鼠肾脏VEGFmRNA及其蛋白质表达明显高于正常对照组(均P<0.01),同时大鼠肾脏出现糖尿病肾病的病理变化;PPAR-γ激动剂罗格列酮干预后,肾组织VEGFmRNA及其蛋白质表达较2型糖尿病组降低(均P<0.01),同时肾脏病理变化也得到明显改善。结论PPAR-γ激动剂罗格列酮可能通过抑制肾脏VEGF表达,延缓糖尿病肾病的发生。
Objective To elucidate the influences of PPAR - γ agonist rosiglitazone on renal expression of VEGF in experimental type 2 diabetic rats. Methods Type 2 diabetes model was induced by long - term high - fat feeding accompanied by intraperitoneal injection of streptozotocin （STZ）. The morphological changes of kidney tissue were detected by light and electron microscopy, Glomerular VEGF mRNA expression and protein synthesis were evaluated by the reverse transcriptionpolymerase chain reaction and immunohistochemical staining respectively. Results Both VEGF mRNA and VEGF protein were higher in type 2 diabetic rats than those in control rats （ P 〈0.01）. Moreover, the main features of the diabetic renal parenchyma were observed in type 2 diabetic rats. The expressions of VEGF mRNA and VEGF protein were decreased after treatment with rosiglitazone（ P 〈0.01）. The renal damage was significantly reduced as well. Conclusion The down - regulation of expression of VEGF by rosiglitazone might prevent diabetic nephropathy.
出处
《中国微循环》
北大核心
2008年第4期211-214,I0003,共5页
Journal of Chinese Microcirculation
基金
河北省卫生厅立项课题(编号:06176)
